Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,465.94
-3.36(-0.06%)
Dow
38,961.45
-150.71(-0.39%)
Nasdaq
17,767.63
+49.98(+0.28%)
Bitcoin USD
61,891.57
+480.13(+0.78%)
CMC Crypto 200
1,281.28
-2.50(-0.20%)

ITCI Dec 2024 60.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

17.93

0.00

(0.00%)

As of 02:32PM EDT. Market open.

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.